nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

14.12.2022 | Research

Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironment

verfasst von: Zhi-chen Guo, Si-li Jing, Sakendeke Jumatai, Zhong-cheng Gong

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

We aimed to determine the significance of Porphyromonas gingivalis (P. gingivalis) in promoting tumour progression in the tumour microenvironment (TME) of oral squamous cell carcinoma (OSCC).

Methods

The Gene Expression Omnibus (GEO) was used to screen out the differentially expressed genes from the two datasets of GEO138206 and GSE87539. Immunohistochemistry and immunofluorescence analysis of samples, cell biological behaviour experiments, and tumour-bearing animal experiments were used to verify the results in vivo and in vitro. The mechanism was revealed at the molecular level, and rescue experiments were carried out by using inhibitors and lentiviruses.

Results

CXCL2 was selected by bioinformatics analysis and was found to be related to a poor prognosis in OSCC patients. Samples with P. gingivalis infection in the TME of OSCC had the strongest cell invasion and proliferation and the largest tumour volume in tumour-bearing animal experiments and exhibited JAK1/STAT3 signalling pathway activation and epithelial-mesenchymal transition (EMT). The expression of P. gingivalis, CXCL2 and TANs were independent risk factors for poor prognosis in OSCC patients. A CXCL2/CXCR2 signalling axis inhibitor significantly decreased the invasion and proliferation ability of cells and the tumour volume in mice. When lentivirus was used to block the CXCL2/CXCR2 signalling axis, the activity of the JAK1/STAT3 signalling pathway was decreased, and the phenotype of EMT was reversed.

Conclusion

Porphyromonas gingivalis promotes OSCC progression by recruiting TANs via activation of the CXCL2/CXCR2 axis in the TME of OSCC.

Nur mit Berechtigung zugänglich

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6:92–113. https://doi.org/10.1038/s41572-020-00224-3CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA: Cancer J Clin 71:7–33. https://doi.org/10.3322/caac.21654CrossRefPubMed

Liu J, Jiang X, Zou A, Mai Z, Huang Z, Sun L, Zhao J (2021) circIGHG-induced epithelial-to-mesenchymal transition promotes oral squamous cell carcinoma progression via miR-142-5p/IGF2BP3 signaling. Can Res 81:344–355. https://doi.org/10.1158/0008-5472.Can-20-0554CrossRef

Amieva M, Peek RM Jr (2016) Pathobiology of helicobacter pylori-induced gastric cancer. Gastroenterology 150:64–78. https://doi.org/10.1053/j.gastro.2015.09.004CrossRefPubMed

Inaba H, Sugita H, Kuboniwa M, Iwai S, Hamada M, Noda T, Morisaki I, Lamont RJ, Amano A (2014) Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation. Cell Microbiol 16:131–145. https://doi.org/10.1111/cmi.12211CrossRefPubMed

Liu XB, Gao ZY, Sun CT, Wen H, Gao B, Li SB, Tong Q (2019) The potential role of P. gingivalis in gastrointestinal cancer: a mini review. Infect Agents Cancer 14:23. https://doi.org/10.1186/s13027-019-0239-4CrossRef

Irfan M, Delgado RZR, Frias-Lopez J (2020) The oral microbiome and cancer. Front Immunol 11:591088. https://doi.org/10.3389/fimmu.2020.591088CrossRefPubMedPubMedCentral

Libby P (2007) Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev 65:S140–S146. https://doi.org/10.1111/j.1753-4887.2007.tb00352.xCrossRefPubMed

Kraus RF, Gruber MA (2021) Neutrophils-from bone marrow to first-line defense of the innate immune system. Front Immunol 12:767175. https://doi.org/10.3389/fimmu.2021.767175CrossRefPubMedPubMedCentral

10.

Giese MA, Hind LE, Huttenlocher A (2019) Neutrophil plasticity in the tumor microenvironment. Blood 133:2159–2167. https://doi.org/10.1182/blood-2018-11-844548CrossRefPubMedPubMedCentral

11.

Sahingur SE, Yeudall WA (2015) Chemokine function in periodontal disease and oral cavity cancer. Front Immunol 6:214. https://doi.org/10.3389/fimmu.2015.00214CrossRefPubMedPubMedCentral

12.

Vashishta A, Jimenez-Flores E, Klaes CK, Tian S, Miralda I, Lamont RJ, Uriarte SM (2019) Putative Periodontal Pathogens, Filifactor Alocis and Peptoanaerobacter Stomatis, induce differential cytokine and chemokine production by human neutrophils. Pathogens (Basel, Switzerland). https://doi.org/10.3390/pathogens8020059CrossRefPubMed

13.

Chen Y, Shao Z, Jiang E et al (2020) CCL21/CCR7 interaction promotes EMT and enhances the stemness of OSCC via a JAK2/STAT3 signaling pathway. J Cell Physiol 235:5995–6009. https://doi.org/10.1002/jcp.29525CrossRefPubMed

14.

Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I (2015) Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer. Clin Exp Metas 32:353–368. https://doi.org/10.1007/s10585-015-9714-5CrossRef

15.

Acharyya S, Oskarsson T, Vanharanta S et al (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150:165–178. https://doi.org/10.1016/j.cell.2012.04.042CrossRefPubMedPubMedCentral

16.

Yu H, Lee H, Herrmann A, Buettner R, Jove R (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14:736–746. https://doi.org/10.1038/nrc3818CrossRefPubMed

17.

Wang J, Lv X, Guo X et al (2021) Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells. Oncogenesis 10:8. https://doi.org/10.1038/s41389-020-00292-wCrossRefPubMedPubMedCentral

18.

Geng F, Liu J, Guo Y, Li C, Wang H, Wang H, Zhao H, Pan Y (2017) Persistent exposure to Porphyromonas gingivalis promotes proliferative and invasion capabilities, and tumorigenic properties of human immortalized oral epithelial cells. Front Cell Infect Microbiol 7:57. https://doi.org/10.3389/fcimb.2017.00057CrossRefPubMedPubMedCentral

19.

Qiu X, Lei Z, Wang Z, Xu Y, Liu C, Li P, Wu H, Gong Z (2019) Knockdown of LncRNA RHPN1-AS1 inhibits cell migration, invasion and proliferation in head and neck squamous cell carcinoma. J Cancer 10:4000–4008. https://doi.org/10.7150/jca.29029CrossRefPubMedPubMedCentral

20.

Guo ZC, Jumatai S, Jing SL, Hu LL, Jia XY, Gong ZC (2021) Bioinformatics and immunohistochemistry analyses of expression levels and clinical significance of CXCL2 and TANs in an oral squamous cell carcinoma tumor microenvironment of Porphyromonas gingivalis infection. Oncol Lett 21:189. https://doi.org/10.3892/ol.2021.12450CrossRefPubMedPubMedCentral

21.

Schmid MC, Khan SQ, Kaneda MM et al (2018) Integrin CD11b activation drives anti-tumor innate immunity. Nat Commun 9:5379. https://doi.org/10.1038/s41467-018-07387-4CrossRefPubMedPubMedCentral

22.

Xue Y, Du HD, Tang D et al (2019) Correlation between the NLRP3 inflammasome and the prognosis of patients with LSCC. Front Oncol 9:588. https://doi.org/10.3389/fonc.2019.00588CrossRefPubMedPubMedCentral

23.

Vyhnalova T, Danek Z, Gachova D, Linhartova PB (2021) The role of the oral microbiota in the etiopathogenesis of oral squamous cell carcinoma. Microorganisms. https://doi.org/10.3390/microorganisms9081549CrossRefPubMedPubMedCentral

24.

Whitmore SE, Lamont RJ (2014) Oral bacteria and cancer. PLoS Pathog 10:e1003933. https://doi.org/10.1371/journal.ppat.1003933CrossRefPubMedPubMedCentral

25.

Damgaard C, Kantarci A, Holmstrup P, Hasturk H, Nielsen CH, Van Dyke TE (2017) Porphyromonas gingivalis-induced production of reactive oxygen species, tumor necrosis factor-α, interleukin-6, CXCL8 and CCL2 by neutrophils from localized aggressive periodontitis and healthy donors: modulating actions of red blood cells and resolvin E1. J Periodontal Res 52:246–254. https://doi.org/10.1111/jre.12388CrossRefPubMed

26.

Kamarajan P, Ateia I, Shin JM, Fenno JC, Le C, Zhan L, Chang A, Darveau R, Kapila YL (2020) Periodontal pathogens promote cancer aggressivity via TLR/MyD88 triggered activation of Integrin/FAK signaling that is therapeutically reversible by a probiotic bacteriocin. PLoS Pathog 16:e1008881. https://doi.org/10.1371/journal.ppat.1008881CrossRefPubMedPubMedCentral

27.

Ibáñez L, de Mendoza I, MaritxalarMendia X, García de la Fuente AM, Quindós Andrés G, Aguirre Urizar JM (2020) Role of Porphyromonas gingivalis in oral squamous cell carcinoma development: a systematic review. J Periodontal Res 55:13–22. https://doi.org/10.1111/jre.12691CrossRef

28.

Harusato A, Viennois E, Etienne-Mesmin L et al (2019) Early-life microbiota exposure restricts myeloid-derived suppressor cell-driven colonic tumorigenesis. Cancer Immunol Res 7:544–551. https://doi.org/10.1158/2326-6066.Cir-18-0444CrossRefPubMedPubMedCentral

29.

Glogauer JE, Sun CX, Bradley G, Magalhaes MA (2015) Neutrophils increase oral squamous cell carcinoma invasion through an invadopodia-dependent pathway. Cancer Immunol Res 3:1218–1226. https://doi.org/10.1158/2326-6066.Cir-15-0017CrossRefPubMed

30.

Lakschevitz FS, Aboodi GM, Glogauer M (2013) Oral neutrophils display a site-specific phenotype characterized by expression of T-cell receptors. J Periodontol 84:1493–1503. https://doi.org/10.1902/jop.2012.120477CrossRefPubMed

31.

El-Bayoumy K, Christensen ND, Hu J et al (2020) An Integrated approach for preventing oral cavity and oropharyngeal cancers: two etiologies with distinct and shared mechanisms of carcinogenesis. Cancer Prev Res (Philadelphia, PA) 13:649–660. https://doi.org/10.1158/1940-6207.Capr-20-0096CrossRef

32.

Zhang Q, Wang J, Yao X et al (2021) Programmed cell death 10 mediated CXCL2-CXCR2 signaling in regulating tumor-associated microglia/macrophages recruitment in glioblastoma. Front Immunol 12:637053. https://doi.org/10.3389/fimmu.2021.637053CrossRefPubMedPubMedCentral

33.

Lin T, Zhang E, Mai PP, Zhang YZ, Chen X, Peng LS (2021) CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. Biosci Rep. https://doi.org/10.1042/bsr20204312

34.

Grépin R, Guyot M, Giuliano S et al (2014) The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Can Res 74:873–883. https://doi.org/10.1158/0008-5472.Can-13-1267CrossRef

35.

Wei ZW, Xia GK, Wu Y et al (2015) CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Cancer Lett 359:335–343. https://doi.org/10.1016/j.canlet.2015.01.033CrossRefPubMed

36.

Susek KH, Karvouni M, Alici E, Lundqvist A (2018) The Role of CXC Chemokine Receptors 1–4 on immune cells in the tumor microenvironment. Front Immunol 9:2159. https://doi.org/10.3389/fimmu.2018.02159CrossRefPubMedPubMedCentral

37.

Chapman RW, Minnicozzi M, Celly CS et al (2007) A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 322:486–493. https://doi.org/10.1124/jpet.106.119040CrossRefPubMed

38.

Lee J, Roberts JS, Atanasova KR, Chowdhury N, Han K, Yilmaz Ö (2017) Human primary epithelial cells acquire an epithelial-mesenchymal-transition phenotype during long-term infection by the oral opportunistic pathogen, Porphyromonas gingivalis. Front Cell Infect Microbiol 7:493. https://doi.org/10.3389/fcimb.2017.00493CrossRefPubMedPubMedCentral

39.

Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, Tsai M, Sadeh J, Magnussen H (2010) SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 35:564–570. https://doi.org/10.1183/09031936.00048509CrossRefPubMed

40.

Guo Z, Jing S-l, Jumatai S et al (2022) Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumor microenvironment, PREPRINT (Version 1) available at Research Square https://doi.org/10.21203/rs.3.rs-1663147/v1

Titel: Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironment
verfasst von: Zhi-chen Guo
Si-li Jing
Sakendeke Jumatai
Zhong-cheng Gong
Publikationsdatum: 14.12.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 6/2023
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-022-03348-5

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironment

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses

BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study

Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Lactate from glycolysis regulates inflammatory macrophage polarization in breast cancer

Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie